BGI Genomics Hits Day Low of CNY 44.70 Amid Price Pressure

BGI Genomics Co., Ltd. experienced a significant decline in its stock performance on March 3, 2026, with a drop of 4.68%. The stock reached an intraday low of CNY 44.70, reflecting ongoing challenges within the company. Over the past week, BGI Genomics has seen a decrease of 7.94%, and its performance over the last month has declined by 10.97%. In a broader context, the stock has underperformed the China Shanghai Composite index, which has shown a modest gain of 0.41% over the same week. Year-to-date, BGI Genomics has recorded a slight decline of 1.28%, contrasting sharply with the index's 2.85% increase. The company has faced persistent difficulties, reporting negative results for 16 consecutive quarters, with net sales declining at an annual rate of 8.44%. Additionally, operating profit has plummeted by 186.74% over the last five years. With a market capitalization of CNY 20,164 million, BGI Genomics continues to navigate a challenging landscape in the pharmaceuticals and biotechnology sector.